Posted by Sara Fazio • January 26th, 2012
In a new study from von Minckwitz et al, bevacizumab added to neoadjuvant combination chemotherapy increased the rate of pathological complete response among patients with HER-2-negative early-stage breast cancer. The effect was greatest in patients with the poorest prognosis, those with so-called triple-negative tumors. The efficacy of neoadjuvant chemotherapy, as measured by the rate of pathological… Read More…
Posted in Physicians-In-Training | Permalink | No Comments
Posted by Rena Xu • January 25th, 2012
The Food and Drug Administration (FDA) recently revoked its approval of the agent bevacizumab (also known as Avastin), a monoclonal antibody against vascular endothelial growth factor A, for treating metastatic breast cancer. Did they act too fast? According to Von Minckwitz et al., bevacizumab, when added to neoadjuvant chemotherapy, may offer considerable benefits for patients… Read More…
Posted in Insights | Permalink | No Comments
Posted by Graham McMahon • March 11th, 2011
The latest article in our Clinical Therapeutics series, Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib, comes from Dr. Vince Cataldo at the Louisiana State University Health Sciences Center and Hematology–Oncology Clinic, Drs. Don Gibbons and Alfonso Quintás-Cardama at Montefiore Medical Center, and Dr. Román Pérez-Soler at Albert Einstein College of Medicine. Advanced-stage non-small-cell… Read More…
Posted in Physicians-In-Training | Permalink | No Comments
Posted by Graham McMahon • November 26th, 2010
The latest article in our Clinical Practice series, “Retinal-Vein Occlusion,” comes from Dr. Tien Wong of the Singapore Eye Research Institute and the Centre for Eye Research Australia, and Dr. Ingrid Scott from the Penn State Hershey Eye Center. Retinal-vein occlusion is a common cause of vision loss in older persons, and the second most… Read More…
Posted in Physicians-In-Training | Permalink | No Comments
